Virtu Financial LLC Takes Position in Oncolytics Biotech Inc. (NASDAQ:ONCY)

Virtu Financial LLC purchased a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 98,452 shares of the company’s stock, valued at approximately $90,000.

Separately, International Assets Investment Management LLC increased its position in Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after purchasing an additional 26,069 shares during the last quarter. 6.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ONCY shares. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Oncolytics Biotech in a report on Monday, March 10th. Royal Bank of Canada dropped their price target on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday, March 10th. Finally, Maxim Group cut their price target on shares of Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Three investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Oncolytics Biotech currently has an average rating of “Buy” and a consensus target price of $4.00.

Oncolytics Biotech Price Performance

Oncolytics Biotech stock opened at $0.60 on Monday. Oncolytics Biotech Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $1.53. The firm has a fifty day moving average price of $0.71 and a two-hundred day moving average price of $0.90. The firm has a market cap of $51.85 million, a price-to-earnings ratio of -2.22 and a beta of 1.18.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.